PHASE 2 CLINICAL EVALUATION OF PRECLINICALLY DEFINED BIOMARKERS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TYROSINE KINASE INHIBITOR (TKI) TIVOZANIB IN RENAL CELL CARCINOMA (RCC)

被引：0
|
作者：
Hutson, T. [1 ]
Rathmell, W. K. [2 ]
Feng, B. [3 ]
Robinson, M. O. [3 ]
Gyuris, J. [3 ]
Lin, J. [3 ]
Choueiri, T. [4 ]
机构：
[1] Baylor Sammons Canc Ctr, GU Oncol Program, Dallas, TX USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, North Carolina Canc Hosp, Chapel Hill, NC 27599 USA
[3] AVEO Oncol, Clin Res, Cambridge, MA USA
[4] Dana Farber Canc Inst, Div Solid Tumor Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu326.66
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
233P
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Establishment of the classifier for a response to vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma
    Go, Heounjeong
    Kang, Mun Jung
    Kim, Pil-Jong
    Park, Ja-Min
    Lee, Jae-Lyun
    Park, Ji Young
    Cho, Yong Mee
    CANCER RESEARCH, 2016, 76
  • [2] Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma
    Go, Heounjeong
    Kang, Mun Jung
    Kim, Pil-Jong
    Lee, Jae-Lyun
    Park, Ji Y.
    Park, Ja-Min
    Ro, Jae Y.
    Cho, Yong Mee
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (01) : 51 - 58
  • [3] Everolimus for Korean patients with metastatic renal cell carcinoma who have failed initial treatment of a vascular endothelial growth factor (VEGF): Tyrosine kinase inhibitor (TKI).
    Park, Kwonoh
    Ahn, Jin-Hee
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    Lee, Jae-Lyun
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Effect of Ketoconazole On Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor
    Cotreau, M.
    Siebers, N.
    Massmanian, L.
    Strahs, A.
    Vargo, D.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 182 - 183
  • [5] The Effect of Rifampin On the Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor
    Cotreau, M.
    Subic, D.
    Massmanian, L.
    Strahs, A.
    Vargo, D.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 183 - 183
  • [6] Bacteriomic profiling reveals potential etiology for vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI)-related diarrhea in patients with metastatic renal cell carcinoma (mRCC)
    Pal, Sumanta K.
    Li, Min
    Wu, Xiwei
    Frankel, Paul
    BJU INTERNATIONAL, 2014, 114 : 13 - 13
  • [7] Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
    Park, Kwonoh
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Seongjoon
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    MEDICAL ONCOLOGY, 2012, 29 (05) : 3291 - 3297
  • [8] Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
    Kwonoh Park
    Jae-Lyun Lee
    Inkeun Park
    Seongjoon Park
    Yongcheol Ahn
    Jin-Hee Ahn
    Shin Ahn
    Cheryn Song
    Jun Hyuk Hong
    Choung-Soo Kim
    Hanjong Ahn
    Medical Oncology, 2012, 29 : 3291 - 3297
  • [9] Effects of Ketoconazole or Rifampin on the Pharmacokinetics of Tivozanib Hydrochloride, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor
    Cotreau, Monette M.
    Siebers, Nicholas M.
    Miller, James
    Strahs, Andrew L.
    Slichenmyer, William
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (02): : 137 - 142
  • [10] Identifying the genomic correlates of clinical benefit (CB) from immunotherapies (IO) and vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKI) in metastatic renal cell carcinoma (mRCC)
    Dizman, Nazli
    Byron, Sara
    Lyou, Yung
    Bergerot, Paulo Gustavo
    Hsu, JoAnn
    Sam, Andre-Philippe
    Trieu, Denise Phan
    Trent, Jeffrey
    Pal, Sumanta Kumar
    CANCER RESEARCH, 2020, 80 (16)
12345